Cevec Pharmaceuticals and Yuhan signed a CAP-Technology license agreement. The license will enable Yuhan to utilize Cevec’s CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.

CAP-T CAP cells are immortalized cell lines for transient and stable protein production developed by Cevec. These nontumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture, and show post-translational modifications that are human-like, including authentic human glycosylation patterns.

“We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with its authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules,” said Dr. Jong-Gyun Kim, head of the Bio-Innovation Unit at Yuhan Research Institute.

It has been a busy year for Cevec, having previously inked three similar partnerships. In November, the company entered a cell-line sales agreement with Catalent Pharma Solutions and also signed a strategic license agreement with CCS Cell Culture Service, enabling CCS to offer its customers transiently transfected CAP-T cells for cell-based assay and protein production applications. In August, Cevec collaborated with Paragon Bioservices, licensing its CAP and CAP-T cell expression system to develop stable cell lines and perform process development for the contract manufacturing of recombinant proteins and antibodies.

Previous articleCrossing the Valley of Death
Next articleHundreds of Mutations Potentially Linked to Autism